Therapeutic compositions to improve the effect of the therapy with anti-Epidermal Growth Factor Receptor antibodies.

Summary of the invention:

The present invention describes specific therapeutic compositions, which increase the efficacy of the therapeutic treatment using monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) in a combination with type I IFNs.